Bank Of New York Mellon Corp Inozyme Pharma, Inc. Transaction History

Bank Of New York Mellon Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$1.3 - $5.73 $61,314 - $270,255	47,165 New	47,165 $270 Million
Q4 2022 Feb 14, 2023	BUY	$1.05 - $2.82 $21,255 - $57,085	20,243 New	20,243 $21,000
Q3 2022 Nov 14, 2022	SELL	$2.57 - $5.45 $4,253 - $9,019	-1,655 Reduced 7.56%	20,243 $54,000
Q2 2022 Aug 15, 2022	SELL	$3.2 - $5.96 $57,968 - $107,965	-18,115 Reduced 45.27%	21,898 $105,000
Q1 2022 May 11, 2022	SELL	$3.87 - $7.55 $4,578 - $8,931	-1,183 Reduced 2.87%	40,013 $164,000
Q4 2021 Feb 11, 2022	BUY	$5.58 - $11.5 $4,341 - $8,947	778 Added 1.92%	41,196 $281,000
Q3 2021 Nov 12, 2021	BUY	$11.12 - $19.4 $43,056 - $75,116	3,872 Added 10.59%	40,418 $469,000
Q2 2021 Aug 11, 2021	BUY	$15.19 - $21.2 $200,644 - $280,030	13,209 Added 56.6%	36,546 $622,000
Q1 2021 May 13, 2021	BUY	$17.77 - $27.9 $35,326 - $55,465	1,988 Added 9.31%	23,337 $462,000
Q4 2020 Feb 09, 2021	BUY	$19.95 - $27.55 $39,181 - $54,108	1,964 Added 10.13%	21,349 $440,000
Q3 2020 Nov 12, 2020	BUY	$17.54 - $30.2 $340,012 - $585,427	19,385 New	19,385 $509,000

53M

3.7K

5.8K

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $118M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.